Novavax, Inc. (BMV:NVAX)

Mexico flag Mexico · Delayed Price · Currency is MXN
141.00
-7.25 (-4.89%)
At close: Mar 28, 2025, 2:00 PM CST
76.25%
Market Cap 19.67B
Revenue (ttm) 14.21B
Net Income (ttm) -3.91B
Shares Out n/a
EPS (ttm) -25.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 958
Average Volume 849
Open 144.20
Previous Close 148.25
Day's Range 141.00 - 144.20
52-Week Range 69.00 - 390.00
Beta n/a
RSI 22.23
Earnings Date May 9, 2025

About Novavax

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1987
Employees 952
Stock Exchange Mexican Stock Exchange
Ticker Symbol NVAX
Full Company Profile

Financial Performance

In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.